In Q1 of 2022, ISR asked 100 people who outsource highly potent drug substance what therapeutic areas their medications are designed to target. The most common response is Oncology with roughly three-quarters of respondents confirming the indication (73 percent). Immunology (36 percent) follows with one-third of respondents targeting the therapeutic area. Hematology (23 percent) and Neurology (22 percent) nearly tie for third position, each with roughly one-quarter of respondents confirming the targeted area. To learn more, follow the link to the Highly Potent API Market Outlook report preview.